المؤلفون: O. N. Egorova, G. M. Tarasova, A. V. Datsina, E. G. Sazhina, О. Н. Егорова, Г. М. Тарасова, А. В. Дацина, Е. Г. Сажина

المساهمون: The article was prepared within the framework of a research work, №/№ of state assignments РК 122040400024-7. The investigation has not been sponsored, Статья подготовлена в рамках научно-исследовательской работы, № государственного задания РК 122040400024-7. Исследование не имело спонсорской поддержки

المصدر: Modern Rheumatology Journal; Том 18, № 3 (2024); 78-84 ; Современная ревматология; Том 18, № 3 (2024); 78-84 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: высокие и низкие дозы, rheumatic diseases, indications for use, high and low doses, ревматические заболевания, показания к назначению

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1592/1475; Bayry J, Misra N, Latry V et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Transfus Clin Biol. 2003 Jun;10(3):165-9. doi:10.1016/s1246-7820(03)00035-1.; Greenberg M, Frant S, Rutstein D. «Gammaglobulin» and «placental globulin»; comparison of their effectiveness in prevention and modification of measles. JAMA. 1944;126(15): 944-47.; Ordman CW, Jennings JR, Janeway CA. Chemical, Clinical and Immunological studies on the products of human plasma fractionation. XII. The Use of Concentrated Normal Human Serum Gamma Globulin (Human Immune Serum Globulin) in the Prevention and Attenuation of Measles. J Clin Invest. 1944 Jul;23(4):541-9. doi:10.1172/JCI101519.; Stokes J, Neefe J. The prevention and attenuation of infectious hepatitis by gamma globulin. Preliminary note. JAMA.1945;127(3): 144-45.; Вruton O. Agammaglobulinemia. Pediatrics.1952;(9):722-28.; Imbach P, Barandun S, Baumgartner C, et al.High-dose intravenous gamma globulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981 Feb;36(1):81-6.; Saeedian M, Randhawa I. Immunoglobulin replacement therapy: a twenty-year review and current update. Int Arch Allergy Immunol. 2014;164(2):151-66. doi:10.1159/000363445. Epub 2014 Jul 10.; Wood JG, Heywood AE, Dennington PM, et al. Trends in intravenous immunoglobulin use in New South Wales, Australia. Intern Med J. 2024 Jan;54(1):149-156. doi:10.1111/imj.16175.; Velikova T, Sekulovski M, Bogdanova S, et al. Intravenous immunoglobulins as immunomodulators in autoimmune diseases and reproductive medicine. Antibodies (Basel). 2023 Mar 2;12(1):20. doi:10.3390/antib12010020.; National Blood Authority. National report on the issue and use of immunoglobulin (IVIg). Annual report 2015–16. Canberra: Common-wealth of Australia; 2017. https://www.blood.gov.au/data-analysis-reporting.; Tavee J, Brannagan TH 3 rd , Lenihan MW, et al. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee. Muscle Nerve. 2023 Oct; 68(4):356-74. doi:10.1002/mus.27922.; Danieli MG, Antonelli E, Auria SS, et al. Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmun Rev. 2023 Nov; 22(11):103451. doi:10.1016/j.autrev.2023.103451.; Hadaschik E, Eming R, French LE, et al. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. Hautarzt. 2020 Jul;71(7):542-52. doi:10.1007/s00105-020-04610-6.; Середавкина НВ, Решетняк ТМ, Насонов ЕЛ. Место внутривенного иммуноглобулина при ревматических заболеваниях. Современная ревматология. 2015;9(4):59-67. doi:10.14412/1996-7012-2015-4-59-67.; Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med. 2012 Nov 22;367(21):2015-25. doi:10.1056/NEJMra1009433.; Лазанович ВА, Просекова ЕВ. Внутривенные иммуноглобулины: механизмы терапевтических эффектов. Медицинская иммунология. 2014;16(4):311-22.; Shoenfeld Y, Gershwin ME. Intravenous immunoglobulin. Clinic Rev Allerg Immunol. 2005;29:165-66. doi:10.1385/CRIAI:29:3:165.; Bayry J,Fournier EM, Maddur MS, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011 Feb;36(1): 9-15. doi:10.1016/j.jaut.2010.09.006. Epub 2010 Dec 9.; Maddur MS, Kaveri SV, Bayry J. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev. 2011 Oct;10(12):809-10. doi:10.1016/j.autrev.2011.02.007. Epub 2011 Mar 2.; Blank M, Bashi T, Shoenfeld Y. Idiotype-specific intravenous immunoglobulin (IVIG) for therapy of autoimmune diseases. Methods Mol Biol. 2014:1060:353-61. doi:10.1007/978-1-62703-586-6_18.; Hulett MD, Hogarth PM. Molecular Basis of Fc Receptor Function. Adv Immunol. 1994; 57:1-127. doi:10.1016/s0065-2776(08)60671-9.; Spahn JD, Leung DY, Chan MT, et al. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol. 1999 Mar;103(3 Pt 1):421-6. doi:10.1016/s0091-6749(99)70466-5.; Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol. 2012 Apr;42(2):247-55. doi:10.1007/s12016-011-8278-7.; Dalakas MC. Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping chronic IVIg therapy. Neurotherapeutics. 2021 Oct;18(4):2397-2418. doi:10.1007/s13311-021-01108-4. Epub 2021 Nov 11.; Benavides-Villanueva F, Loricera J, Calvo-Rio V, et al, Intravenous immunoglobulin therapy in antineutrophil cytoplasmic antibody-associated vasculitis. Eur J Intern Med. 2023 Nov;117:78-84. doi:10.1016/j.ejim.2023.06.021.; Yates M, Watts AR, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi:10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23.; Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007 Mar;6(4):257-9. doi:10.1016/j.autrev.2006.08.011. Epub 2006 Aug 28.; Aggarwal R, Schessl J, Charles-Schoeman C, et al. Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study. Arthritis Res Ther. 2024 Jan 17;26(1):27. doi:10.1186/s13075-023-03232-2.; Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005 Dec;29(3):219-28. doi:10.1385/CRIAI:29:3:219.; Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol. 2005 Apr;66(4):395-402. doi:10.1016/j.humimm.2005.01.022.; Sherer Y, Kuechler S, Jose Scali J, et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J. 2008 Jan;10(1):55-7.; Binello N, Cancelli C, Passalacqua S, et al. Use of intravenous immunoglobulin therapy at unconventional doses in refractory fulminant systemic lupus erythematosus. Eur J Case Rep Intern Med. 2018 Sep 27;5(9):000934. doi:10.12890/2018_000934. eCollection 2018.; Schroeder J, Zeuner AR, Euler HH, Lцffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: Clinical and serological results of a pilot study. J Rheumatol. 1996 Jan;23(1):71-5.; Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus. 1999;8(9):705-12. doi:10.1191/096120399678841007.; Tenti S, Cheleschi S, Guidelli GM, et al. Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature. Autoimmun Rev. 2016 Mar;15(3):226-35. doi:10.1016/j.autrev.2015.11.009. Epub 2015 Dec 1.; Sciascia S, Giachino O, Roccatello D. Prevention of thrombosis relapse in anti-phospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin. Clin Exp Rheumatol. 2012 May-Jun;30(3):409-13. Epub 2012 Jun 26.; Ruiz-Irastorza G, Espinosa G, Frutos M, et al. Diagnosis and treatment of lupus nephritis: Consensus document from the systemic autoimmune disease group (GEAS) of the Spanish Society of Internal Medicine (SEMI) and the Spanish Society of Nephrology (S.E.N.). Nefrologia. 2012:32 Suppl 1:1-35. doi:10.3265/Nefrologia.pre2011.Dec.11298.; Caccavo D, Vaccaro F, Ferri GM, et al. Antiidiotypes against antiphospholipid anti-bodies are present in normal polyspecific immunoglobulins for therapeutic use. J Autoimmun. 1994 Aug;7(4):537-48. doi:10.1006/jaut.1994.1039.; Horn HC, Grau K, Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus. 2004;13(6):478-80. doi:10.1191/0961203303lu1035cr.; Mulhearn B, Bruce IN. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford). 2015 Mar;54(3):383-91. doi:10.1093/rheumatology/keu429. Epub 2014 Nov 17.; Bitsadze V, Yakubova F, Khizroeva J, et al. Catastrophic Antiphospholipid Syndrome. Int J Mol Sci. 2024 Jan 4; 25(1):668. doi:10.3390/ijms25010668.; Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: A series of 73 patients. Arthritis Care Res (Hoboken). 2010 Dec;62(12):1748-55. doi:10.1002/acr.20325.; Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009 May-Jun;187(3):201-6. doi:10.1007/s00408-009-9146-6. Epub 2009 Apr 22.; Cherin P, Pelletier S, Teixeira A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: An open study with thirty-five adult patients. Arthritis Rheum. 2002 Feb;46(2):467-74. doi:10.1002/art.10053.; Speca S, Farhat MM, Jendoubi M, et al. Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis. Sci Rep. 2023 Sep 12;13(1):15102. doi:10.1038/s41598-023-42464-9.; Tandaipan J, Guillen-Del-Castillo A, Simeуn-Aznar CP, et al. Immunoglobulins in systemic sclerosis management. A large multi-center experience. Autoimmun Rev. 2023 Nov; 22(11):103441. doi:10.1016/j.autrev.2023.103441.; Matsuda KM, Yoshizaki A, Kuzumi A, et al. Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford). 2023 Sep 1; 62(9):3139-45. doi:10.1093/rheumatology/kead093.; Blank M, Levy Y, Amital H, et al. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in high skin mice. Arthritis Rheum. 2002 Jun;46(6):1689-90. doi:10.1002/art.10363.; Richter C, Schnabel A, Csernok E, et al. Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol. 1995 Jul;101(1):2-7. doi:10.1111/j.1365-2249.1995.tb02268.x.; Aries PM, Hellmich B, Gross WL. Intravenous immunoglobulin therapy in vasculitis. Clin Rev Allergy Immunol. 2005 Dec;29(3): 237-45. doi:10.1385/CRIAI:29:3:237.; Kivity S, Katz U, Daniel N, et al. Evidence for the use of intravenous immunoglobulins – a review of the literature. Clin Rev Allergy Immunol. 2010 Apr;38(2-3):201-69. doi:10.1007/s12016-009-8155-9.; Chung SA, Langford CA, Maz M, et al. 2021 american college of rheumatology/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021 Aug;73(8):1088-1105. doi:10.1002/acr.24634. Epub 2021 Jul 8.; Hellmich В, Sanchez-Alamo В, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024 Jan 2; 83(1):30-47. doi:10.1136/ard-2022-223764.; Jayne D, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000 Jul;93(7):433-9. doi:10.1093/qjmed/93.7.433.; Shimizu T, Morita T, Kumanogoh A. The therapeutic efficacy of intravenous immunoglobulin in anti-neutrophilic cytoplasmic antibody-associated vasculitis: A meta-analysis. Rheumatology (Oxford). 2020 May 1; 59(5):959-967. doi:10.1093/rheumatology/kez311.; Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6): 488-98. doi:10.7326/0003-4819-116-6-488.; Martinez V, Cohen P, Pagnoux C, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: Results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008 Jan;58(1):308-17. doi:10.1002/art.23147.; Fortin PM, Tejani AM, Bassett K, Musini V. Intravenous immunoglobulin as adjuvant therapy for Wegener’s granulomatosis. Cochrane Database Syst Rev. 2013 Jan 31;2013(1): CD007057. doi:10.1002/14651858.CD007057.pub3.; Weishaupt C, Strölin A, Kahle B, et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1784-1791. doi:10.1111/jdv.15639. Epub 2019 May 14.; Ozden MG, Ozdemir H, Senturk N. Intravenous immunoglobulin in resistant livedoid vasculopathy: analysis of a case series. Dermatol Ther. 2020 Mar;33(2):e13229. doi:10.1111/dth.13229. Epub 2020 Feb 4.; Kofler K, Strölin A, Geiger V, Kofler L. Intravenous immunoglobulin therapy in livedoid vasculopathy: retrospective observation of clinical outcome and patient's activity level. J Cutan Med Surg. 2021 Sep;25(5):504-10. doi:10.1177/12034754211003525.; Cantarini L, Stromillo ML, Vitale A, et al. Efficacy and Safety of Intravenous Immunoglobulin Treatment in Refractory Behcet's Disease with Different Organ Involvement: A Case Series. Isr Med Assoc J. 2016 Mar-Apr;18 (3-4):238-42.; Seeliger T, Prenzler NK, Gingele S, et al. Neuro-Sjцgren: Peripheral Neuropathy With Limb Weakness in Sjцgren’s Syndrome. Front Immunol. 2019 Jul 11:10:1600. doi:10.3389/fimmu.2019.01600. eCollection 2019.; Mehmood M, Jog A, Niazi M, et al. Atypical 's syndrome initially presenting as lymphocytic interstitial pneumonitis followed by immune thrombocytopenia. Case Rep Rheumatol. 2021 Mar 15;2021:6681590. doi:10.1155/2021/6681590.; Noh G, Han CW. Intravenous Immune Globulin (IVIG) Therapy After Unsuccessful Treatment with Corticosteroid and Cyclosporine A in Pfeifer-Weber-Christian Disease: A Case Report. Am J Case Rep. 2021 Jan 4; 22:e929519. doi:10.12659/AJCR.929519; Shen X, Wang F. The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: A propensity score-matched pilot study. Int J Rheum Dis. 2023 Sep; 26(9):1745-1750. doi:10.1111/1756-185X.14808.; Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev. 2015 Aug; 14(8):651-8. doi:10.1016/j.autrev.2015.04.003. Epub 2015 Apr 12.; Muscat C, Bertotto A, Ercolani R, et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis. 1995 May;54(5): 382-5. doi:10.1136/ard.54.5.382.; Kanik KS, Yarboro CH, Naparstek Y, et al. Failure of low-dose intravenous immunoglobulin therapy to suppress disease activity in patients with treatment-refractory rheumatoid arthritis. Arthritis Rheum. 1996 Jun;39(6): 1027-9. doi:10.1002/art.1780390621.; Maksymowych WP, Avina-Zubieta A, Luong M, Russell AS. High dose intravenous immunoglobulin (IVIG) in severe refractory rheumatoid arthritis: no evidence for efficacy. Clin Exp Rheumatol. 1996 Nov-Dec;14(6): 657-60.; Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized placebo controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol. 1994 Dec;21(12):2353-8.; https://mrj.ima-press.net/mrj/article/view/1592

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1592
https://doi.org/10.14412/1996-7012-2024-3-78-84

المؤلفون: O. N. Egorova, B. S. Belov, E. G. Sazhina, О. Н. Егорова, Б. С. Белов, Е. Г. Сажина

المصدر: Modern Rheumatology Journal; Том 15, № 3 (2021); 75-80 ; Современная ревматология; Том 15, № 3 (2021); 75-80 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: шкала оценки коморбидности CIRS, lipodermatosclerosis, comorbidity, Charlson index, scale for assessing comorbidity CIRS, липодерматосклероз, коморбидность, индекс Charlson

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1152/1113; https://mrj.ima-press.net/mrj/article/view/1152/1114; Campbell-Scherer D. Multimorbidity challenge ofevidence-based medicine. Evid Based Med. 2010 Dec;15(6):165-6. doi:10.1136/ebm1154.; Насонов ЕЛ, Гордеев АВ, Галушко ЕА. Ревматические заболевания и многоморбидность. Терапевтический архив. 2015;87(5):4-9.; Вербовая АФ, Цанава ИА, Вербовая НИ. Медицина XXI века: в фокусе коморбидность.Университетская медицина Урала. 2017;(2):27-31.; Litwin MS, Greenfield S, Elkin EP. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007 May 1;109(9):1777-83. doi:10.1002/cncr.22615.; Von Korff MA, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992 Feb; 45(2):197-203. doi:10.1016/0895-4356(92)90016-g.; Starfield B, Weiner J, Mumford L. Ambulatory care groups: a categorization of diagnoses for research and management. Health Serv Res. 1991 Apr;26(1):53-74.; Rozzini R, Frisoni GB, Barbisoni P, et al. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbid¬ity. Age Ageing. 2002 Jul;31(4): 277-85. doi:10.1093/ageing/31.4.277.; Kaplan MH, Feinstein AR. Acritique of methods in reported studies of long-term vascular complications in patients with diabetes mellitus. Diabetes. 1973 Mar;22(3):160-74. doi:10.2337/diab.22.3.160.; Parkerson GR Jr, Broadhead WE, Tse CK. The Duke Severity of Illness Checklist (DUSOI) for measurement of severity and comorbidity. J Clin Epidemiol. 1993 Apr;46(4): 379-93. doi:10.1016/0895-4356(93)90153-r.; Charlson ME, Pompei P, Ales HL. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi:10.1016/0021-9681(87)90171-8.; Сарсенбаева ГИ, Турсынбекова АЕ. Современные подходы к оценке коморбидности у пациентов. CardioСоматика. 2019;(1):19-23.; Miller MD, Towers A. Manual of guidelines for scoring the cumulative illness rating scale for geriatrics (CIRS-G). Pittsburg: University of Pittsburgh; 1991. 31 p.; Greenfield S, Apolone G. The importance of coexistent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement: comorbidity and outcomes after hipreplacement. Med Care. 1993 Feb;31(2): 141-54. doi:10.1097/00005650-199302000-00005.; Grolla DL, Tob T, Bombardiere C. The development of a comorbidity index with physical function as the outcome. J Clin Epidemiol. 2005 Jun;58(6):595-602. doi:10.1016/j.jclinepi.2004.10.018.; De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003 Mar;56(3):221-9. doi:10.1016/s0895-4356(02)00585-1.; Radner H. Multimorbidity in rheumatic conditions. Wien Klin Wochenschr. 2016 Nov; 128(21-22):786-90. doi:10.1007/s00508-016-1090-x. Epub 2016 Oct 13.; Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi:10.1186/ar2669. Epub 2009 May 19.; Панафидина ТА, Кондратьева ЛВ, Герасимова ЕВ и др. Коморбидность при ревматоидном артрите. Научно-практическая ревматология. 2014;52(3):283-9.; Клюквина НГ. Проблема коморбидности при системной красной волчанке. Русский медицинский журнал. 2015;(7): 370-4.; Балабанова РМ. Анкилозирующий спондилит и коморбидность: безопасность длительного применения нимесулида. Современная ревматология. 2017;11(4): 79-82.; Wick MR. Panniculitis: a summary. Semin Diagn Pathol. 2017 May;34(3):261-72. doi:10.1053/j.semdp.2016.12.004. Epub 2016 Dec 27.; Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. Jul-Aug 2010;23(4):375-88. doi:10.1111/j.1529-8019.2010.01338.x.; Егорова ОН, Белов БС, Глухова СИ, Раденска-Лоповок СГ. Липодерматосклероз как разновидность лобулярного панникулита: клинические особенности. Клиницист. 2015;(9):28-34.; Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004 Dec;40(6):1248-52. doi:10.1016/j.jvs.2004.09.027.; Савельев ВС, Гологорский ВА, Кириенко АИ и др. Флебология. Руководство для врачей. Москва: Медицина; 2001.; Ocampo VD, Gladman M. Psoriatic arthritis Version 1. F1000Res. 2019 Sep 20; 8:F1000 Faculty Rev-1665. doi:10.12688/f1000research.19144.1. eCollection 2019.; Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994 Jan 15;120(2):104-10. doi:10.7326/0003-4819-120-2-199401150-00002.; Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review. https://seer.cancer.gov/archive/csr/1975_2007/; Никитина НМ, Афанасьев ИА, Ребров АП. Коморбидность у больных ревматоидным артритом. Научно-практическая ревматология. 2015;53(2):149-54.; Nikitina NM, Afanas'ev IA, Rebrov AP. Comorbidity in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya. 2015;53(2):149-54. (In Russ.).; Baillet A, Gossec L, Carmona L, et al. Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumaticdiseases in daily practice: a EULAR initiative. Ann Rheum Dis. 2016 Jun;75(6):965-73. doi:10.1136/annrheumdis-2016-209233. Epub 2016 Mar 16.; Frewen J, Hughes AJ, Denny J, Natkunarajah J. Lipodermatosclerosis of the pendulous abdomen. Clin Exp Dermatol. 2020 Jul;45(5):626-7. doi:10.1111/ced.14210. Epub 2020 Apr 22.; Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the framingham study. Comparative Study Am J Epidemiol. 1997 Mar 1;145(5):408-15. doi:10.1093/oxfordjournals.aje.a009122.; Essers I, Stolwijk С, Boonen А, et al. Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study. Multicenter study. Ann Rheum Dis. 2016 Jan;75(1):203-9. doi:10.1136/annrheumdis-2014-206147. Epub 2014 Oct 31.; https://mrj.ima-press.net/mrj/article/view/1152

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1152
https://doi.org/10.14412/1996-7012-2021-3-75-80

المؤلفون: O. N. Egorova, B. S. Belov, E. G. Sazhina, О. Н. Егорова, Б. С. Белов, Е. Г. Сажина

المساهمون: The investigation has been conducted within scientific topic №0397-2020-0006 «Innovative technologies for the diagnosis and treatment of systemic connective tissue diseases»., Работа выполнена в рамках научной исследовательской работы «Инновационные технологии диагностики и лечения системных заболеваний соединительной ткани» (ИКБРС 0397-2020-0006).

المصدر: Modern Rheumatology Journal; Том 15, № 5 (2021); 108-113 ; Современная ревматология; Том 15, № 5 (2021); 108-113 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: ревматические заболевания, botulinum toxin type A, rheumatic diseases, ботулинический токсин типа А

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1208/1162; Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333. doi:10.1016/j.ejpain.2005.06.009.Epub 2005 Aug 10.; Екушева ЕВ. Коморбидный пациент с хроническим болевым синдромом. Русский медицинский журнал. 2019;(9):44-8.; http://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf; Насонова ВА, Каратеев АЕ. Симптоматическая терапия боли при ревматических заболеваниях: место ацеклофенака. Современная ревматология. 2009;3(3):58-65.; Zhai S, Huang B, Yu K. The efficacy and safety of Botulinum Toxin Type A in painful knee osteoarthritis: a systematic review and meta-analysis. J Int Med Res. 2019 Dec 29: 300060519895868. doi:10.1177/0300060519895868.; Костенко ЕВ, Коновалова ЗН, Орлова ОР, Хатькова СЕ. Ботулотоксин при болевых синдромах. Медицинский совет. 2018;(1):58-63.; Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinumtoxin type A. Neurotoxicology. 2005 Oct;26(5):785-93. doi:10.1016/j.neuro.2005.01.017. Epub 2005 Jul 5.; Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48-56. doi:10.1002/ana.410330109.; Gobel H, Heinze A, Heinze-Kuhn K, Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain. 2001 Apr;91(3): 195-9. doi:10.1016/S0304-3959(01)00292-5; Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother. 2001 Oct;2(10):1649-54. doi:10.1517/14656566.2.10.1649.; Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. Jul-Aug 2003;43 Suppl 1: S9-15. doi:10.1046/j.1526-4610.43.7s.3.x.; Gazerani P, Staahl C, Drewes AM, Arendt-Nielsen L. The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain. 2006 Jun;122(3):315-25. doi:10.1016/j.pain.2006.04.014. Epub 2006 May 4.; Gazerani P, Pedersen NS, Staahl C, et al. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009 Jan;141(1-2):60-9. doi:10.1016/j.pain.2008.10.005. Epub 2008 Nov 11.; Артемьев ДВ, Орлова ОР, Моренкова АЭ. Использование ботокса в медицинской практике. Неврологический журнал.2000;5(4):46-51.; Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun. 2013 Oct;81(10): 3894-902. doi:10.1128/IAI.00536-13. Epub 2013 Aug 5.; Pier CL, Chen C, Tepp WH, et al. Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett. 2011 Jan 3;585(1):199-206. doi:10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.; Akaike N, Shin MC, Wakita M, et al. Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol. 2013 Feb 15;591(4):1031-43. doi:10.1113/jphysiol.2012.242131. Epub 2012 Oct 29.; Mahowald ML, Singh JA, Dykstra D. Long term effects of intra-articular botulinum toxin A for refractory joint pain. Neurotox Res. 2006 Apr;9(2-3):179-88. doi:10.1007/BF03033937.; Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. Joint Bone Spine. 2009 Mar;76(2):190-4. doi:10.1016/j.jbspin.2008.05.006. Epub 2008 Oct 25.; Singh JA, Mahowald ML, Kushnaryov A, et al. Repeat injections of intra-articular botulinum toxin a for the treatment of chronic arthritis joint pain. J Clin Rheumatol. 2009 Feb;15(1):35-8. doi:10.1097/RHU.0b013e3181953b14.; Singh JA, Mahowald ML, Noorbaloochi S. Intra-articular botulinum toxin A for refractory shoulder pain: a randomized, double-blinded, placebo-controlled trial. Transl Res. 2009 May;153(5):205-16. doi:10.1016 /j.trsl.2009.02.004. Epub 2009 Mar 13.; Kidd BL. Osteoarthritis and joint pain. Pain. 2006 Jul;123(1-2):6-9. doi:10.1016/j.pain.2006.04.009. Epub 2006 May 22.; Martell-Pelletier J, Barr AJ, Cicuttini FM, et al. Osteoarthritis. Nat Rev Dis Primers. 2016 Oct 13;2:16072. doi:10.1038/nrdp.2016.72.; Ivanusic JJ. Molecular Mechanisms That Contribute to Bone Marrow Pain. Front Neurol. 2017 Sep 11;8:458. doi:10.3389/fneur.2017.00458. eCollection 2017.; Khenioui H, Houvenagel E, Catanzariti JF, et al. Usefulness of intra-articular botulinum toxin injections. A systematic review. Joint Bone Spine. 2016 Mar;83(2):149-54. doi:10.1016/j.jbspin.2015.10.001. Epub 2015 Nov 29.; Schaible HG, Ebersberger A, von Banchet GS. Mechanisms of pain in arthritis. Ann N Y Acad Sci. 2002 Jun;966: 343-54. doi:10.1111/j.1749-6632.2002.tb04234.x.; Hsieh LF, Wu CW, Chou CC, et al. Effects of botulinum toxin landmark-guided intra-articular injection in subjects with knee osteoarthritis. PM R. 2016 Dec;8(12): 1127-35. doi:10.1016/j.pmrj.2016.05.009. Epub 2016 May 19.; Chou CL, Lee SH, Lu SY, et al. Therapeutic effects of intra-articular botulinum neurotoxin in advanced knee osteoarthritis. J Chin Med Assoc. 2010 Nov; 73(11):573-80. doi:10.1016/S1726-4901(10)70126-X.; Cinone N, Letizia S, Santoro L, et al. Intra-articular injection of botulinum toxin type A for shoulder pain in glenohumeral osteoarthritis: a case series summary and review of the literature. J Pain Res. 2018 Jun 25;11:1239-45. doi:10.2147/JPR.S159700.eCollection 2018.; Joo YJ, Yoon SJ, Kim CW. A comparison of the short-term effects of a botulinum toxin type a and triamcinolone acetate injection on adhesive capsulitis of the shoulder. Ann Rehabil Med. 2013 Apr;37(2):208-14. doi:10.5535/arm.2013.37.2.208. Epub 2013 Apr 30.; Sun SF, Hsu CW, Lin HS, et al. Efficacy of intraarticular botulinum toxin A and intraarticular hyaluronate plus rehabilitation exercise in patients with unilateral ankle osteoarthritis: a randomized controlled trial. J Foot Ankle Res. 2014 Feb 6;7(1):9. doi:10.1186/1757-1146-7-9.; Singh JA, Mahowald ML, Noorbaloochi S. Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: a randomized controlled trial. J Rheumatol. 2010 Nov; 37(11):2377-86. doi:10.3899/jrheum.100336.Epub 2010 Sep 1.; Arendt-Nielsen L, Jiang G, De Gryse R, Turkel C. Intra-articular onabotulinumtoxin A in osteoarthritis knee pain: Effect on human mechanistic pain biomarkers and clinical pain. Scand J Rheumatol. 2017 Jul; 46(4):303-16. doi:10.1080/03009742.2016.1203988. Epub 2016 Oct 13.; McAlindon TE, Schmidt U, Bugarin D, et al. Efficacy and safety of single-dose onabotulinumtoxinA in the treatment of symptoms of osteoarthritis of the knee: results of a placebo-controlled, double-blind study. Osteoarthritis Cartilage. 2018 Oct;26(10): 1291-9. doi:10.1016/j.joca.2018.05.001. Epub 2018 May 9.; Плотникова ЕВ, Елькин ВД, Миронов АН и др. Экпериментальное обоснование к использованию в косметической практике нового отечественного иммунобиологического препарата с миорелаксатным действием «релатокс». Биология и экпериментальная медицина. 2011; XXVIII(4):125-30.; Batifol D. Different types of injection in temporomandibular disorders (TMD) treatment. Rev Stomatol Chir Maxillofac Chir Orale. 2016 Sep;117(4):256-8. doi:10.1016/j.revsto.2016.07.005. Epub 2016 Aug 23.; Sycha T, Graninger M, Auff E, Shinider P. Botulinum toxin in the treatment of Raynaud phenomenon: A pilot study. Eur J Clin Invest. 2004 Apr;34(4):312-3. doi:10.1111/j.1365-2362.2004.01324.x.; Asad U, Austin B, Tarbox M, Paulger B. Botulinum toxin in the long-term treatment of refractory Raynaud's phenomenon. J Drugs Dermatol. 2019 Sep 1;18(9):943-5.; Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012 Apr; 148(4):426-8. doi:10.1001/archdermatol.2011.1144.; Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin. Plast Reconstr Surg. 2007 Jan;119(1):217-26. doi:10.1097/01.prs.0000244860.00674.57.; Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010 Dec;35(12):2085-92. doi:10.1016/j.jhsa.2010.09.019.; Bello RJ, Cooney CM, Melamed E, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017 Aug;69(8):1661-9. doi:10.1002/art.40123. Epub 2017 Jun 26.; Serri J, Legre R, Veit V, et al. Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013 Dec;58(6): 658-62. doi:10.1016/j.anplas.2011.11.001.Epub 2011 Dec 26.; Motegi S, Yamada K, Toki S, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016 Jan;43(1): 56-62. doi:10.1111/1346-8138.13030. Epub 2015 Jul 15.; Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018 Dec;5(4):224-9. doi:10.5152/eurjrheum.2018.18013. Epub 2018 Oct 12.; Herrick AL. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol. 2012 Aug;8(8):469-79. doi:10.1038/nrrheum.2012.96. Epub 2012 Jul 10.; Wigley FM. Clinical practice Raynaud's phenomenon. N Engl J Med. 2002 Sep 26; 347(13):1001-8. doi:10.1056/NEJMcp013013.; Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004 Jan;107(1-2):125-33. doi:10.1016/j.pain.2003.10.008.; Stone AV, Koman AL, Callahan MF, et al. The effect of botulinum neurotoxin-A on blood flow in rats: a potencial mechanism for treatment of Raynaud phenomenon. J Hand Surg Am. 2012 Apr;37(4):795-802. doi:10.1016/j.jhsa.2012.01.021. Epub 2012 Mar 3.; Setler P. Therapeutic use of botulinum toxins: back-ground and history. Clin J Pain. Nov-Dec 2002;18(6 Suppl):S119-24. doi:10.1097/00002508-200211001-00002.; O'Neil LM, Palme CE, Riffat F, Mahant N. Botulinum toxin for the management of Sjö gren syndrome-associated recurrent parotitis. J Oral Maxillofac Surg. 2016 Dec; 74(12):2428-30. doi:10.1016/j.joms.2016.06.169. Epub 2016 Jun 18.; Daniel SJ, Diamond M. Botulinum toxin injection: a novel treatment for recurrent cystic parotitis Sjö gren syndrome. Otolaryngol Head Neck Surg. 2011 Jul;145(1):180-1. doi:10.1177/0194599811398596.; Spiera H, Asbell PA, Simpson DM. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1997 Sep;24(9):1842-3.; Francis IC, Coroneo MT. Botulinum toxin increases tearing in patients with Sjö gren's syndrome: a preliminary report. J Rheumatol. 1998 Sep;25(9):1859.; https://mrj.ima-press.net/mrj/article/view/1208

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1208
https://doi.org/10.14412/1996-7012-2021-5-108-113

المؤلفون: O A Antelava, I S Denisov, E G Sazhina, Rimma Mikhailovna Balabanova, A N Pogodina, E I Shmidt, Yu A Olyunin, E L Nasonov, Ольга Алексеевна Антелава, И. С. Денисов, Е. Г. Сажина, Римма Михайловна Балабанова, А. Н. Погодина, Е. И. Шмидт, Юрий Алексанрович Олюнин, Евгений Львович Насонов

المصدر: Modern Rheumatology Journal; Том 6, № 1 (2012); 29-31 ; Современная ревматология; Том 6, № 1 (2012); 29-31 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2012-1

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/397/375; Насонов Е.Л., Штутман В.З. Фармакотерапия идиопатических воспалительных миопатий. Клин. фармакол. 1995; 4(2): 57—63. Dalakas M.C. Polymyositis, Dermatomyositis and Inclusion-body myositis. New Engl J Med 1992; 325(21): 1487—98. Насонов Е.Л., Штутман В.З., Саложин К.В. и др. Клинико-иммунологическая гетерогенность идиопатических воспалительных миопатий. Клин. мед. 1995; 2: 3-8. Идиопатические воспалительные миопатии. Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова М., 2005; 192-201. Bohan A., Peter J. Polymyositis and Dermatomyositis (First of two parts). New Engl J Med 1975; 292(7): 344—45. Mastaglia F.L., Zilko P.J. Inflammatory myopathies: how to treat the difficult cases. J Clin Neurosci 2003; 10(1): 99—101.; https://mrj.ima-press.net/mrj/article/view/397

الاتاحة: https://mrj.ima-press.net/mrj/article/view/397
https://doi.org/10.14412/1996-7012-2012-712

المؤلفون: Boris Sergeyevich Belov, O N Egorova, S G Radenska-Lopovok, R M Balabanova, E G Sazhina, M E Tsanyan, Б. С. Белов, О. Н. Егорова, Римма Михайловна Балабанова, Е. Г. Сажина, М. Е. Цанян

المصدر: Modern Rheumatology Journal; Том 3, № 3 (2009); 45-49 ; Современная ревматология; Том 3, № 3 (2009); 45-49 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2009-3

مصطلحات موضوعية: панникулит, vasculitis, panniculitis, васкулит

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/242/237; https://mrj.ima-press.net/mrj/article/view/242

الاتاحة: https://mrj.ima-press.net/mrj/article/view/242
https://doi.org/10.14412/1996-7012-2009-557

المؤلفون: Olga Alekseyevna Antelava, G M Tarasova, E G Sazhina, Yu A Olyunin, R M Balabanova, E L Nasonov, Ольга Алексеевна Антелава, Г. М. Тарасова, Е. Г. Сажина, Юрий Алексанрович Олюнин, Римма Михайловна Балабанова, Евгений Львович Насонов

المصدر: Modern Rheumatology Journal; Том 3, № 4 (2009); 54-58 ; Современная ревматология; Том 3, № 4 (2009); 54-58 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2009-4

مصطلحات موضوعية: антисинтетазный синдром, dermatomyositis, antisynthetase syndrome, дематомиозит

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/259/254; Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003;362:971. Plotz P.H., Dalakas M., Leff R.L. et al. Current concepts in the idiopathic inflammatory myopathies: Polymyositis, dermatomyositis and related disorders. Ann Intern Med 1989;111-43. Идиопатические воспалительные миопатии. Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М., 2005;192-201. Бондаренко И.Б., Мухин Н.А., Насонов Е.Л. и др. Поражение легких при полимиозите и дерматомиозите. Клин мед 1998;2:20-4. O'Leary P.A., Waisman M. Dermatomyositis: A study of forty cases. Arch Derm Syph 1940;41:1001-19. Антелава О.А., Бондаренко И.Б., Хитров А.Н. и др. Поражение дыхательной системы при полимиозите/дерматомиозите. РМЖ 2008;16(24)334:1633-7. Насонов Е.Л., Штутман В.З., Саложин К.В. и др. Клинико-иммунологическая гетерогенность идиопатических воспалительных миопатий. Клин мед 1995;2:3-8. Santy A., Rochat Th., Schoch O.D. et al. Pulmonary fibrosis with predominant CDg lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J 1997;10:2907-12. Targoff J.N., Amett F.C Clinical manifestation in patients with antibody to PL-12 antigen. Am J Med 1990;88:241-51. Hashish L., Trieu E.P., Sadanandan P. et al. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome (absract). Arthritis Rheum 2005;52(Suppl. 9):312. Betteridge Z., Gunawardena H., North J. et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) assotiated with polymyositis and interstitial pneumonia. Rheumatol 2007;46:10058. Targoff I.N. Autoantibodies and their significance in myositis. Curr Rheumatol Rep 2008;10(4):333-40. Yoshifuji H., Fujii T., Kobayashi S. et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006;39:233-41. Fathi М., Vikgren J., Boijsen M. et al. Interstitial lung disease in Polymyositis and Dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis and Rheumatusm (Arthritis Care and Research). May 15 2008;59(5):677-85. Kalluri M., Sahn S.A., Oddis C.V. еt al. Clinical Profile of Anti-PL-12 Autoantibody: Cohort Study and Review of the Literature. Chest Feb 18 2009;[Epub ahead of print]. Bohan A., Peter JB. Polymyositis and dermatomyositis (first of two parts). N EngI J Med 1975;292:344-7. Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403. Антелава О.А., Насонов Е.Л. Современные методы оценки активности и повреждения при идиопатических воспалительных миопатиях. Науч-практич ревматол 2007;1:59-62. Fujisawa T., Isuda Т., Nakamura Y. et al. Differences in Clinical Features and Prognosis of Interstitial Lung Diseases Between Polymyositis and Dermatomyositis. The Journal of Rheumatology 2005;32(1):58-64. Yang C.J., Sheu C.C., Ou T.T. et al. Combined lung fibrosis and 'mechanic's hand': a clinical diagnostic clue to amyopathic antisynthetase syndrome. Respirology. Jun 13 2008;4:611-4. Chen I.J., Jan Wu Y.J. et all. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol Feb 27 2009.; https://mrj.ima-press.net/mrj/article/view/259

الاتاحة: https://mrj.ima-press.net/mrj/article/view/259
https://doi.org/10.14412/1996-7012-2009-574

المؤلفون: O N Egorova, R M Balabanova, N E Lopatina, A K Kaptayeva, T P Fedina, E G Sazhina, E L Nasonov, G N Chuvirov, О. Н. Егорова, Римма Михайловна Балабанова, Н. Е., А. К. Каптаева, Т. П. Федина, Е. Г. Сажина, Евгений Львович Насонов, Г. Н. Чувиров

المصدر: Modern Rheumatology Journal; Том 3, № 2 (2009); 42-47 ; Современная ревматология; Том 3, № 2 (2009); 42-47 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2009-2

مصطلحات موضوعية: Ацикловир, herpesviruses, Panavir®, acyclovir, герпесвирусы, Панавир®

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/224/219; Kelaidi C., Tulliez M., Lecoq-Lafon C. et al. Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. Leukemia 2002;16(10):2173-4. Torre-Cisneros J., Del Castillo M., Castцn J.J. et al. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatology 2005;44(9):1132-5. Curtis J.R., Patkar N., Xie A. et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56(4):1125-33. Balandraud N., Guis S., Meynard J.B. et al. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum 2007;57(5):762-7. Belin V., Tebib J., Vignon E. Cytomegalovirus infection in a patient with rheumatoid arthritis. Joint Bone Spine 2003;70(4):303-6. Kojima M., Motoori N., Itoh H. et al. Disnribution of Epstein-Barr virus in systemic rheumatic disease ( rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis) with associated lymphadenopathy: a study of 49 cases. Int J Surg Pathol 2005;13(3):273-8. Chim C.S., Pang Y.Y., Ooi G.C. et al. EBV-associated synovial lymphoma in a chronically inflamed joint in rheumatoid arthritis receiving prolonged methotrexate treatment. Haematologica 2006;91 (8 Suppl):ECR31. Balandraud N., Roudier J., Roudier C. What are the links between Epstein-Barr virus, lymphoma and tumor necrosis factor antagonism in rheumatoid arthritis? Semin Arthritis Rheum 2005;34(5 Suppl 1):31-3. Исаков В.А., Архипова Е.И., Исаков Д.В. Герпесвирусные инфекции человека. СПб., 2006; с. 12-150. Alvarez-Lafuente R., Fernandez-Gutierrez B., de Miguel S. et al. Potential relationship between herpes viruses and rheumatoid arthritis: analysis with quantitative real time polymerase chain reaction. Ann Rheum Dis 2005;64(9):1357-9. Zaher S.S., Sandinha T., Roberts F. et al. Herpes simplex keratitis misdiagnosed as rheumatoid arthritis-related peripheral ulcerative keratitis. Cornea 2005;24(8):1015-7. Баринский И.Ф., Бикбулатова Р.М. Герпесвирусные инфекции (диагностика и лечение). М., 1990; с. 77-81. Сомов Е.Е. Герпетические и эпидемические вирусные кератоконъюнктивиты. СПб., 1996. Шабалин А.Р., Конопля Е.А., Конопля А.И. Влияние комплексной терапии на показатели иммунного статуса и клинику урогенитального герпеса. Вестн дерматол венерол 2004;2:48-50. Posnett D.N., Yarilin D. Amplification of autoimmune disease by infection. Art Res Ther 2005;7:74-84. Чувиров Г.Н., Маркова Т.П. Актуальные вопросы противовирусной терапии. РМЖ 2002;10(3):115-8. Сергиенко В.И. Противовирусные свойства препарата «Панавир». М., 2005;5-111. Grootscholten C., Ligtenberg G., Hagen E.C. et al. Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int 2006;70(4):732-42. Wolfe F., Michaud K., Chakravarty E.F. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and noninflammatory musculoskeletal disorders. Rheumatology 2006;45(11):1370-5. Beam T.R., Gilbert D.N., Kunin C.M. Европейское руководство по клинической оценке противоинфекционных лекарственных средств. М., 1996;119-26. Fujinami R.S., von Herrath M.G., Christen U. et al. Molecular mimicry, bystanderactivation, or viral persistence: infections and autoimmune disease. Clin Microb Rev 2006;19(1):80-94. Dworkin R.H., Johnson R.W., Breuer J. et al. Management of Herpes Zoster. Clinical Ifect Dis 2007:44:1-26. Mancuso R., Delbue S., Borghi E. Increased prevalence of varicella zoster virus DNA in cerebrospinal fluid from patients with multiple sclerosis. J Med Virol 2007;79(2):192-9. Егорова О.Н., Балабанова Р.М. Противовирусная терапия при ревматических заболеваниях. Фарматека 2007;6:90-4. Петров А.В., Дударь Л.В., Малый К.Д. Персистенция различных инфекционных агентов в мононуклеарных лейкоцитах крови в дебюте ревматоидного артрита. Тер арх 2004;5:78-81. Agarwal V., Singh R., Chauhan S. Remission of rheumatoid arthritis after acute disseminated varicella-zoster infection. Clin Rheumatol 2006;21:1-2. Izumikawa K., Morinaga Y., Kondo A. et al. Adult Still's disease associated with cytomegalovirus infection. J Infect Chemother 2007;13(2):114-7. Балабанова Р.М., Сальникова Т.С., Сороцкая В.Н. Первый опыт применения противовирусного препарата цимевена в комплексной терапии ревматоидного артрита. Ревматология 2001;5:87-91.; https://mrj.ima-press.net/mrj/article/view/224

الاتاحة: https://mrj.ima-press.net/mrj/article/view/224
https://doi.org/10.14412/1996-7012-2009-539